Mgmt has been under immense pressure from SHs in recent weeks to focus cash reserves on #AVCT Tx.
Through extensive conversations, my view is that they have listened. They are acutely aware that the value upside in Tx is of course infinitely...
3/9
@GarethP76@Ophidian18@RAH00084@avacta ...greater than in Dx. It would be a dereliction of BoD's duty to SHs to raise cash (or use existing cash) to make another £25m+ Dx acquisition.
I'm now sure that that will not happen. Existing BS cash will see #AVCT through to end 2024 (at least). That includes funding... 4/9
The science is sound. Everyone knows that by now, surely. Dox is dox, it'll do its job when deposited in the TME in significant quantities. This will be proved in P1b (IMO).
To reiterate: SP did not collapse because of poor data.
[On the contrary, as I Tweeted recently, #AVCT has been a victim of its own success (in terms of P1a taking much longer than ever expected, owing to the MTD still not being found)]
6/9
My view (/understanding) is that mgmt will not be stupid with capital allocation. Greater value upside resides in Tx over Dx (that's just common sense and basic business!).
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6